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Abstract  
Purpose: The emergence of prostate cancer as a major health issue and the absence of curative treatment for 
metastatic disease requires the development of new treatment modalities. Prostate specific antigen (PSA) and 
prostate-specific membrane antigen (PSMA) are possible targets for prostate cancer immunotherapy. We have 
previously shown that PSA and PSMA can be expressed in recombinant bacille Calmette-Guérin (BCG) strains. 
Methods: The in vivo immunogenicity of the prostate-specific proteins produced by this recombinant BCG strain 
were examined by detection of specific antibody responses and delayed-type hypersensitivity (DTH) responses in 
mice vaccinated with these strains. These immune responses were compared with those of control mice vaccinated 
with phosphate buffered saline diluent or soluble PSA or PSMA. 
Results: Mice vaccinated with rBCG-PSA developed low levels of anti-PSA antibodies and strong DTH to PSA.  
Mice vaccinated with rBCG-PSMA developed strong DTH to PSMA and no anti-PSMA antibodies.   
Conclusions: We conclude that recombinant BCG expressing PSA or PSMA induce strong cellular immune 
responses to these antigens. We propose that the innate adjuvant capacity of BCG could help stimulate a specific 
immune response against prostate-specific proteins produced by the bacteria, which in turn, could lead to the 
eradication of undetected metastatic prostate cancer cells in post-surgical patients. 
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Introduction 
The emergence of prostate cancer (CaP) as a major health issue and the absence of curative 
treatment for metastatic disease necessitate the development of new treatment modalities. In 
1990, CaP surpassed lung cancer as the most commonly diagnosed cancer among American 
men[1]. Approximately 233,00 cases, or twenty-seven percent of all newly diagnosed cancers in 
American men in 2014 will be CaP[2]. One in six American men will be diagnosed with CaP in 
his lifetime[1], and this cancer is the second leading cause of cancer deaths in American men 
with approximately 29,480 deaths estimated for the year 2014[1]. 
  Ninety percent of organ-confined CaP cases can be cured with surgery if discovered early, but 
because there is no effective systemic therapy for this disease, the prognosis is poor once the 
tumor has spread beyond the gland itself and about half of the patients with CaP have clinically 
advanced (extraprostatic/extracapsular) disease at the time of initial diagnosis[3]. Even in those 
patients initially determined to have organ-confined disease, one-third actually have undetected 
micrometastatic disease, as determined by subsequent pathological staging or disease 
progression[4]. In all, more than 65% of patients with CaP develop metastatic disease. 
  Due to the high failure rate of conventional therapies (surgery, radiation, hormonal), current 
research efforts are focused on alternative approaches for the treatment of metastatic prostate 
cancer such as immunotherapy [4, 5]. Immunotherapy for the treatment of metastatic prostate 
cancer is based on the activation of the host’s immune response against tumor-associated 
antigens (TAA) present on tumor cells that distinguish them from normal cells. TAA may be 
normal, tissue-specific cellular proteins that are upregulated on cancer cells, mutated proteins, 
oncofetal antigens, growth factor receptors, oncogene and tumor-suppressor gene products, 
among others [6]. 
Prostate cancer is an ideal candidate for immunotherapy for many reasons. There is a 
substantial failure rate of current therapies for the primary tumor and a lack of effective 
chemotherapy for metastatic disease. The prostate contains organ-specific TAA that can serve as 
targets of an immune response. The prostate is not essential and its removal or destruction in 
many patients with CaP eliminates the concern for potential autoimmune disease [7]. 
  Prostate-specific antigen (PSA) and prostate specific membrane antigen (PSMA) are two 
prostate-specfic TAA. PSA is expressed almost exclusively in normal, benign, and malignant 
prostate cells. Circulating PSA levels are frequently elevated with primary, locally recurrent or 
metastatic prostate cancer [8] PSMA is predominantly found in the prostate and is upregulated in 
primary and metastatic prostate cancer. Moreover, PSMA has been observed in endothelial cells 
of capillary beds in certain tumors including those of the prostate. Therefore, PSMA may be 
targeted in tumor neovasculature as well as in carcinoma cells[9]. 
We have previously reported development of recombinant BCG (rBCG) strains that express 
PSA and PSMA with the goal of using such recombinant BCG as cancer vaccines in treatment of 
CaP. The current report describes the stimulation of cellular and humoral immune responses 
against these prostate specific molecules in mice vaccinated with these recombinant BCG. We 
propose that recombinant BCG may elicit a specific immune response against the 
prostate-specific antigens it produces which in turn may lead to the eradication of undetected 
metastatic prostate cancer cells that express these proteins. 
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Materials and methods 
Mice 
 Six to ten week old (C57BL/6 x BALB/c) F1 (CBF1) mice were obtained from Jackson 
Laboratories (Bar Harbor, Maine). The animals were housed 5 per cage in the Department of 
Comparative Medicine Animal Facility of New York Medical College that is accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Expression of recombinant PSA and PSMA in BCG. (A) Expression of PSA in BCG. Lane 1, 
LNCaP prostate cancer cell lysate (positive control); Lane 2, recombinant BCG expressing RAS protein 
(negative control); Lane 3, BCG-PSA lysate; Lane 4, BCG-PSMA1300 lysate. Recombinant full length 
PSA consistently appears as a doublet of approximately 33 kDa (Figure 1A, lane 3). The larger of the two 
molecules may be full length PSA still covalently associated with the antigen 85B signal sequence 
encoded in the pMM7 expression vector. (B) Expression of PSMA in BCG. Lane 1, influenza virus lysate 
(HA serotype, X-47E4940) (positive control); Lane 2, influenza virus lysate (HA serotype PR8 E5201) 
(negative control); Lane 3, BCG vector lysate control; Lane 4, BCG-PSMA1300 lysate, BCG-PSMA 
1300 appears as a doublet of approximately 50-55 kDa. As with PSA protein, the larger of the two 
molecules may be PSMA covalently associated with the antigen 85B signal sequence. Lane 5, BCG-PSA 
lysate. Molecular weight determination was made using Life Technologies high molecular weight protein 
markers. 
Recombinant Bacteria 
 BCG were engineered to express PSA or PSMA as previously described [10]. Briefly, the entire 
coding region of PSA was cloned into the pMM7 vector. Following electroporation into BCG 
and antibiotic resistance selection, clones expressing PSA protein were identified by western 
blot analysis (Figure 1a) [10].  
  The prostate cancer cell line, LNCaP, grown in RPMI 1640 medium, supplemented with 10% 
FCS (Mediatech, Cellgro, Herndon, VA) was used as a positive control for PSA protein 
expression. The LnCaP cells were lysed in lysis buffer (10 mM tris, 1 mM EDTA, 15 mM NaCl, 
10% NP-40) containing protease inhibitors (1 microgram/ml of aprotinin, leupeptin, and 17 
micrograms/ml PMSF). PSA protein expression was quantified using known amounts of purified 
human PSA as standards on western blot, followed by densitometry (Table 1). 
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Table 1 Levels of protein expression in rBCG lysates. Amounts of protein expression were 
quantified using serial dilutions of standards on western blots, followed by densitometry. 
 
 
 
 
 
 
 
 
 
 
 
 The entire coding region of PSMA was cloned into the pMM7-HA vector as well as two 
overlapping fragments of PSMA [10]. One PSMA fragment contained the 5’- 1314 nucleotides 
encoding the amino-terminal 437 amino acids of PSMA. The second PSMA fragment contained 
the 3’- 1483 nucleotides of PSMA encoding the 446 carboxyl-terminal amino acids. The 
pMM7-HA vector expresses recombinant proteins as a fusion molecule with the hemagglutinin 
tag epitope, used for detection purposes[10]. Following electroporation and antibiotic resistance 
selection, clones expressing PSMA protein were identified by western blot analysis. Both PSMA 
fragments are efficiently expressed in BCG. BCG-PSMA1300, which expresses the 
amino-terminal fragment of PSMA, was used for vaccination experiments (Figure 1b). Influenza 
viral lysates were used as positive and negative controls for the HA tag (a gift from Dr. Edwin 
Kilbourne, NYMC, Valhalla NY). PSMA protein expression in lysates was quantified using 
serial dilutions of a known 30 kD HA tagged molecular weight markers as standards on western 
blot, followed by densitometry (Table 1). 
Prostate Specific Molecules  
Human seminal PSA was obtained from Scripps Laboratories (San Diego, CA). Recombinant 
PSMA was prepared using the MaxBac2.0 Baculovirus Expression system. (Invitrogen, Carlsbad, 
CA).  
Immunization of mice  
CBF1 mice were subcutaneously injected with one million colony-forming units of BCG-PSA, 
BCG-PSMA1300 (expressing the 5'-1314 nucleotides encoding the amino terminal 438 amino 
acids of PSMA) [10]BCG (with vector only), 5 micrograms of PSA protein, 5 micrograms of 
PSMA protein or PBS (100 microliters total volume).    
Detection of DTH 
Animals were challenged 12 weeks after vaccination with 10 micrograms PSA or 5 micrograms 
PSMA in 10 microliters of saline into the footpad using 100ul Hamilton syringe fitted with a 30 
or 26 gauge needle. Footpad thickness was measured by a vernier caliper, prior to and 24 and 48 
hours after challenge [11]Statistical analysis was performed using one-way analysis of variance 
Bacterial Clone Level of Protein Expression 
ng per microgram of bacterial protein 
 
BCG-PSA 
 
24.00 
BCG-PSMA 
 
0.24 
BCG-PSMA1300 0.66 
BCG-PSMA1500 0.47 
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(ANOVA) analysis with a Tukey-Kramer multiple comparison post-test.(Figure 2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Analysis of DTH response. Mice were challenged with either soluble PSA (Panel A) or PSMA 
(Panel B) and the response was quantified by increased footpad thickness (black bars, 24hours;white 
hatched bars, 48 hours) as well as histologic evaluation of infiltrating cells (48 hours). 
Detection of an Antibody Response  
Individual samples of serum were collected from each mouse by retro-orbital bleeding prior to, 
and 5 and 10 weeks after immunization. Equal amounts of sample from animals in each group 
were pooled. ELISA was used to assay for anti-PSA and PSMA antibodies. Ninety six-well 
Immunlon-2 plates were coated with 100 ng/well of PSA in 100 microliters of coating buffer 
(0.1 M NaHCO3 pH 9.6). The plates were incubated overnight at 370C after which the excess 
liquid was decanted. One hundred micrograms of PSMA was solubilized in 8M urea, then coated 
onto wells and incubated overnight at 40C after which the excess liquid was decanted, the plate 
was rinsed once with PBS. The plates were blocked with 200 microliters of 5% BSA in PBS per 
well for 1 hour at room temperature. Samples in PBS containing 1% BSA and 0.05% Tween-20 
were then added to the wells (total volume, 100 microliters per well) and incubated for 1 hour at 
room temperature. Preimmune sera were diluted 1:20 and the post-immune sera were 2-fold 
serially diluted (1:20 to 1:2560). The plate was washed 5 times with 0.05% Tween-20 in PBS 
and once with PBS. HRP-labeled, secondary antibody, rabbit anti-mouse IgG (H+L) (Jackson 
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ImmunoResearch Laboratories, West Grove, PA) was added at a 1:1000 dilution at 100 
microliters per well in 1% BSA, 0.05% Tween-20 in PBS. The plate was incubated for 1 hour at 
room temperature and washed as above. Colorimetric analysis was performed using TMB 
Microwell Peroxidase Substrate System (Kirkegaard and Perry Laboratories, Inc., Gaithersburg, 
MD)(Figure 4). Endpoints for antibody titers were defined as the highest dilution at which the 
values of absorbance at 450nm (A450) were greater than the pre-immune sera, diluted 1:20, plus 
2 standard deviations [12].  
Results  
Recombinant BCG express high levels of recombinant proteins  
Of the four recombinant prostate molecule constructs, PSA was synthesized at the highest level, 
perhaps due to its smaller size and higher hydrophilicity than PSMA (Table 1). Perhaps for the 
same reasons, both fragments of PSMA were synthesized at higher levels than the entire 
molecule (Table 1). Recombinant full length PSA consistently appears as a doublet of 
approximately 33 kDa (Figure 1A). The larger of the two molecules may be full length PSA still 
covalently associated with the antigen 85B signal sequence encoded in the pMM7 expression 
vector. BCG-PSMA 1300 appears as a doublet of approximately 50-55 kDa (Figure 1B). As with 
PSA, the larger of the two molecules may be PSMA still covalently associated with the antigen 
85B signal sequence. BCG-PSA and BCG-PSMA 1300 (because of its higher expression) were 
used for the immunization of mice. 
  Mice immunized with BCG-PSA or BCG-PSMA1300 develop a DTH response against 
the respective prostate specific molecule 
To determine if vaccination with recombinant BCG can stimulate a DTH response in animals 
challenged with a target protein, groups of 5 immunized and control mice were injected with 10 
micrograms of PSA or 5 micrograms PSMA protein into the hind footpad twelve weeks after 
vaccination. Footpad thickness was measured 24 and 48 hours later. 
BCG-PSA and BCG-PMSA vaccination induced specific DTH as measured by increases in 
footpad thickness that were maximal at 24 h that could only be elicited by the homologous 
protein antigen. Thus, mice immunized with BCG-PSA only exhibited a significant increase in 
footpad thickness to PSA protein (Figure 2A), while mice immunized with BCG-PMSA only 
exhibited a significant increase in footpad thickness to PMSA protein (Figure 2B). These data 
suggest that immunization with recombinant BCG that express prostate specific molecules can 
stimulate cellular immune responses against the recombinant proteins. 
Mice immunized with BCG-PSA generate a weak antibody response to PSA  
Serum was prepared from mice 5 and 10 weeks after immunization and assayed for the presence 
of anti-PSA or anti-PSMA antibodies. Mice immunized with human PSA had a titer of 1:1250 
antibody at 5 weeks, which decreased to 1:160 by week 10 (Figure 3). Mice immunized with 
BCG-PSA also had an anti-PSA antibody response, but this response was not detectable until 
week 10 after vaccination and had a lower titer, 1:320. BCG with vector alone was unable to 
stimulate an anti-PSA antibody response and showed a profile similar to vaccination with PBS. 
Similar results were obtained in a second experiment (data not shown). There was no detectable 
antibody response against PSMA in any animals immunized with PSMA or BCG-PSMA1300. 
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Figure 3 Antibody response to PSA by mice immunized with BCG-PSA. Mice were immunized with PBS, 
PSA, BCG-PSA or BCG-PSMA1300 and serum was tested for the presence of anti-PSA antibodies by 
ELISA. Sera not showing a response at the lowest dilution tested, 1/10, were assigned a titer of 10. 
Discussion 
It has been over a century since William Coley’s first report of cancer regression induced by 
immune system activation in response to bacterial toxins[6]. Immunotherapy has always 
represented an attractive approach to cancer treatment in light of the many shortcomings of 
conventional treatment such as surgery, radiation and chemotherapy[6]. While many cancer 
vaccine trials have yielded promising results, active immunotherapy has only recently become 
an established modality of anticancer therapy[13]. The high incidence of metastatic prostate 
cancer necessitates the development of new systemic therapies.   
 One immunotherapeutic approach for cancer involves the use of a patient’s tumor cells mixed 
with various adjuvants, including cytokines, or genetically modified autologous cells that 
secrete cytokines[3]. Among the drawbacks of whole cell vaccines is that it is labor-intensive 
and time consuming, especially if the cells are to be genetically modified. The success, or the 
lack of success, in the expansion of primary cultures for autologous vaccines can limit the 
courses of vaccinations and, further, an autologous vaccine needs to be specifically made for 
each patient[14].  
  Another strategy for generating antigen-specific immunity is the ex vivo administration of 
specific antigen or peptides to antigen-presenting cells (APC). Again, this type of therapy is 
limited by the need to culture cells from each patient and success in the expansion of primary 
cultures for autologous vaccines can limit the number of courses of vaccination. Further, the use 
of peptides to “ load” APCs faces the obstacle of finding HLA-restricted peptides for all the 
different polymorphic HLA molecules[3]. 
The use of recombinant BCG that express prostate specific molecules for immunotherapy would 
eliminate the necessity to collect, expand, and preserve autologous tumor cells. Also, BCG 
engenders a strong, long-lived immune response due to the ability to survive for several weeks 
in the host’s macrophages and this may eliminate the need for numerous vaccine boosts. Live 
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BCG is currently used as the vaccine for tuberculosis and its safety is already well established. 
This is beneficial due to the fact that live, antigen-expressing recombinant BCG appear to be 
critical for providing strong, specific, cell-mediated immunity; dead recombinant BCG and live 
non-recombinant BCG mixed with antigens are significantly less effective [15]. 
 We have demonstrated that recombinant BCG are capable of eliciting an immune response 
against PSA and PSMA. Delayed type hypersensitivity was induced against both PSA and 
PSMA. A delayed antibody response to PSA in animals vaccinated with BCG-PSA was observed 
compared to vaccination with human PSA. This delay could indicate that live recombinant BCG 
cells are actively growing and continued growth may be necessary to achieve a critical mass of 
recombinant bacteria and foreign antigen needed for the stimulation of the immune response[16]. 
It is noteworthy that BCG has a long doubling time of approximately 20 hrs. It is possible that a 
longer period of observation may be necessary to obtain an even higher anti-PSA antibody titer 
from animals immunized with BCG-PSA. 
 The recombinant BCG vaccine, BCG-PSMA1300 was not capable of eliciting an antibody 
response. These results suggest that even though cellular responses were detected, the inherent 
immunogenicity and/or level of antigen expression may be important for engendering a strong 
humoral response[16]. The BCG-PSA vaccine expressed approximately forty-fold more 
recombinant protein that BCG-PSMA1300.  
 The ability of the recombinant BCG vaccines to elicit a cell-mediated immune response is 
more desirable than its ability to elicit a humoral response. It has been shown that a 
cell-mediated response is more efficient in eliminating tumor cells. Studies in experimental 
animals have shown that cellular rather than humoral immune responses are responsible for the 
rejection of transplanted tumors or allogeneic tissue and that the administration of antibodies has 
had little impact on inhibiting the growth of tumors[17].  
  Clinically, it would be anticipated that recombinant BCG vaccines would be administered to 
patients who have recently undergone a radical prostatectomy, as the low tumor burden may 
present a window of opportunity for the recombinant BCG vaccine to stimulate an immune 
response against prostate molecules, and eradicate metastatic prostate cancer cells. It is 
significant that Wei et al. [18]have reported that transgenic BALB/c mice that express human 
PSA in a tissue-specific and androgen-dependent manner are capable of mounting a cytotoxic 
immune response against PSA. Thus, the induction of anti-PSA or anti-PSMA immune 
responses in prostate cancer patients with recombinant BCGimmunotherapeutic vaccines 
appears feasible. Further, other prostate-associated proteins may be used as additional targets for 
recombinant BCG immunotherapy, as well as the incorporation of recombinant cytokine 
expression to direct and enhance the immune response against prostate cancer cells. 
In summary, we have shown that immunization of mice with recombinant BCG expressing 
prostate-specific antigens induces readily detectable, specific, cell mediated immune responses 
to PSA and PSMA, suggesting that these vaccines could be used to stimulate a prostate specific 
immune response for the eradication of undetected metastatic prostate cancer after radical 
prostatectomy. 
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